Pfizer To Provide US Additional 10M Courses Of COVID-19 Oral Therapy

• The U.S. government has committed to purchasing an additional 10 million treatment courses of Pfizer Inc's (NYSE:PFE) COVID-19 oral therapy, Paxlovid. 
• This commitment will supplement the 10 million treatment courses previously contracted by the U.S. Government, bringing the total amount of treatment courses to 20 million. 
• Collectively, approximately 10 million PAXLOVID treatment courses have been accelerated for delivery by the end of June, with the remaining 10 million to follow by the end of September.
• The agency recently authorized the emergency use of Paxlovid for mild-to-moderate COVID-19 in adults and pediatric patients.
• Price Action: PFE shares are down 2.71% at $55.12 during the market session on the last check Tuesday.